Is Oxytocin Application for Autism Spectrum Disorder Evidence-Based?

Citations Over TimeTop 10% of 2015 papers

Abstract

Autism spectrum disorder (ASD) is characterized by persistent deficits within two core symptom domains: social communication and restricted, repetitive behaviors. Although numerous studies have reported psychopharmacological treatment outcomes for the core symptom domains of ASD, there are not enough studies on fundamental treatments based on the etiological pathology of ASD. Studies on candidate medications related to the pathogenesis of ASD, such as naltrexone and secretin, were conducted, but the results were inconclusive. Oxytocin has been identified as having an important role in maternal behavior and attachment, and it has been recognized as a key factor in the social developmental deficit seen in ASD. Genetic studies have also identified associations between ASD and the oxytocin pathway. As ASD has its onset in infancy, parents are willing to try even experimental or unapproved treatments in an effort to avoid missing the critical period for diagnosis and treatment, which can place their child in an irreversible state. While therapeutic application of oxytocin for ASD is in its early stages, we have concluded that oxytocin would be a promising therapeutic substance via a thorough literature review focusing on the following: the relationship between oxytocin and sociality; single nucleotide polymorphisms as a biological marker of ASD; and validity verification of oxytocin treatment in humans. We also reviewed materials related to the mechanism of oxytocin action that may support its potential application in treating ASD.

Related Papers

• → The role of oxytocin in parturition(2003)269 cited
• → Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour(2000)184 cited
• → Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour(2000)150 cited
• → Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin(2005)38 cited
• → Progesterone metabolite and spontaneous myometrial contractions in vitro(1999)42 cited